Advancing Ocular Gene Therapies
Developments in biotech and gene therapy continue to capture the attention of the inherited retinal disease and broader ocular health community. According to a press release from Eli Lilly and Company, a definitive agreement has been reached for Lilly to acquire Adverum Biotechnologies, Inc., bringing focus to clinical-stage intravitreal gene therapies designed to preserve sight.
Key Terms and Asset Details
Under the terms of the definitive agreement, Lilly will initiate a tender offer to acquire all outstanding shares of Adverum common stock. The agreement includes $3.56 per share in cash payable at closing, alongside a non-transferrable contingent value right (CVR) providing up to an additional $8.91 per share based on specific milestone achievements.
The acquisition centers on Adverum's lead product candidate, Ixo-vec, an investigational intravitreal gene therapy currently being evaluated for wet age-related macular degeneration (wAMD). According to the companies, Ixo-vec is designed as a single administration therapy intended to deliver continuous intraocular aflibercept levels, aiming to reduce the treatment burden associated with chronic anti-VEGF therapies. The candidate is currently being studied in the Phase 3 ARTEMIS clinical trial and has received Fast Track, Regenerative Medicine Advanced Therapy (RMAT), PRIME, and Innovation Passport designations from regulatory bodies including the U.S. FDA.
Potential Impact on Patients and Families
For patients and families navigating chronic retinal conditions, the burden of frequent, repeated intraocular injections presents significant challenges. Therapies focused on single-administration delivery models are designed to alleviate this routine while maintaining stable therapeutic levels. While Ixo-vec targets wAMD, advancements in intravitreal gene delivery platforms hold broader interest for communities affected by progressive vision loss.
Looking Ahead
As part of the transaction process, Lilly has also entered into a promissory note to provide Adverum with secured financing of up to $65 million to support ongoing clinical trials and development activities leading up to the transaction's completion. The acquisition is anticipated to close in the fourth quarter of 2025, subject to customary closing conditions and the tender of a majority of Adverum's outstanding shares.